Depdc5 Deficiency Exacerbates Alcohol-Induced Hepatic Steatosis via Suppression of PPARα Pathway

Researchers found that aberrant activation of mTORC1 was likely attributed to the reduction of DEP domain-containing protein 5 in the livers of ethanol-fed mice or alcohol-related liver disease patients.
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

Share

Collagen and Elastic Fibres in Acute and Chronic Liver Injury

Researchers investigated whether immunohistochemistry and multiplexing for collagen type (I & III) and elastic fibers and a modified Victoria blue method could be helpful.
[Scientific Reports]
Full Article
Bookmark

No account yet? Register

Share

Dietary Carbohydrates and Fats in Nonalcoholic Fatty Liver Disease

Scientists review cross-sectional studies on dietary habits of patients with nonalcoholic fatty liver disease and randomized controlled trials on the effects of altering dietary macronutrients on intrahepatic triglyceride.
[Nature Reviews Gastroenterology & Hepatology]
Abstract
Bookmark

No account yet? Register

Share

Sorafenib Fails to Trigger Ferroptosis across a Wide Range of Cancer Cell Lines

Using a combination of well-defined genetically engineered tumor cell lines and canonical small molecule ferroptosis inhibitors, scientists provided unequivocal evidence that sorafenib did not induce ferroptosis in a series of tumor cell lines unlike the cognate system xc inhibitors sulfasalazine and erastin.
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

Share

Parthenolide, Bioactive Compound of Chrysanthemum parthenium L., Ameliorates Fibrogenesis and Inflammation in Hepatic Fibrosis via Regulating the Crosstalk of TLR4 and STAT3 Signaling Pathway

Scientists focused on the regulatory effects of parthenolide, a bioactive component derived from Chrysanthemum parthenium L., against hepatic fibrosis via regulating the crosstalk of toll-like receptor 4 and signal transducer and activator of transcription 3 in activated hepatic stellate cells.
[Phytotherapy Research]
Abstract
Bookmark

No account yet? Register

Share

Single-Nucleus RNA-seq2 Reveals Functional Crosstalk between Liver Zonation and Ploidy

Scientists developed a single-nucleus RNA-seq2 method tailored for the comprehensive analysis of the nuclear transcriptome from frozen tissues, allowing the dissection of all cell types present in the liver, regardless of cell size or cellular fragility.
[Nature Communications]
Full Article
Bookmark

No account yet? Register

Share

Hepatitis B Virus Evades Immune Recognition via RNA Adenosine Deaminase ADAR1-Mediated Viral RNA Editing in Hepatocytes

Scientists identified adenosine deaminases acting on RNA 1 (ADAR1), which was a key factor in Hepatitis B virus evasion from interferon responses in hepatocytes.
[Cellular & Molecular Immunology]
Abstract
Bookmark

No account yet? Register

Share

Compensatory Hepatic Adaptation Accompanies Permanent Absence of Intrahepatic Biliary Network Due to YAP1 Loss in Liver Progenitors

Researchers detected Yes-associated protein 1 (YAP1) activity in biliary cells and in cells at the hepatobiliary bifurcation in single-cell RNA sequencing analysis of developing livers
[Cell Reports]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Adenine Base Editing Reduces Misfolded Protein Accumulation and Toxicity in Alpha-1 Antitrypsin Deficient Patient iPSC-Hepatocytes

Researchers applied adenine base editors to correct the Z mutation in patient-induced pluripotent stem cells (iPSCs) and iPSC-derived hepatocytes.
[Molecular Therapy]
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Green Synthesis of Gold Nanoparticles from Dendrobium officinale and Its Anticancer Effect on Liver Cancer

In order to evaluate the anti-tumor efficiency and biosafety, the inhibitory rate of HepG2 cells and survival rate of L02 cells were performed in vitro, and the immunohistochemical analysis of H&E, Ki-67, and TUNEL staining were conducted in vivo.
[Drug Delivery]
Full Article
Bookmark

No account yet? Register

Share

Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study

Can-Fite BioPharma Ltd. announced it has completed preparatory work ahead of the anticipated initiation of patient enrollment for its pivotal Phase III registration trial of Namodenoson in the treatment of hepatocellular carcinoma, the most common form of liver cancer.
[Can-Fite Biopharma Ltd.]
Press Release
Bookmark

No account yet? Register

Share
Share